Navacaprant

Navacaprant
Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140; NMRA-335140
Identifiers
	IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine;
CAS Number	2244614-14-8;
PubChem CID	137434175;
ChemSpider	78316413;
UNII	XK5ILZ28KI;
KEGG	D12869;
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C;
	InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3; Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N;

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder and bipolar depression.^[1]^[2]^[3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.^[2] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.^[2]^[4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.^[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.^[5]

Quick facts Clinical data, Other names ...

[1]

[2]

[3]

[4]

[5]

Navacaprant

See also

References

External links

Wikiwand - on